Wiggins, Barbara S.
Senfield, Jeffrey
Kassahun, Helina
Lira, Armando
Somaratne, Ransi
Funding for this research was provided by:
Amgen
Article History
First Online: 6 March 2018
Compliance with Ethical Standards
:
: Barbara S. Wiggins has served as a consultant for Amgen Inc. Helina Kassahun, Armando Lira, and Ransi Somaratne are employees of Amgen Inc. and hold Amgen stock and/or stock options. Ransi Somaratne is an inventor on at least one pending patent application owned by Amgen Inc. relating to evolocumab. Jeffrey Senfield declares no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.